973 Program(No.2011CB504001);the National Natural Science Foundation of China(Nos.81322010,81170735 and 81200582);the Drug Innovation Program of the National Science and Technology Project(No.2011ZX09307-001-02);863 Program(No.2012AA02A509);Excellent Young Medical Expert of Shanghai(No.XYQ2011041);Shanghai Talent Development Grant(No.2012041);National Young Top Talent Supporting Program
Gliclazide used for the treatment of type 2 diabetes mellitus(T2DM) stimulates insulin secretion and influences peripheral blood monocytes.The roles of gliclazide in peripheral monocytes of newly diagnosed T2 DM pat...
supported by grants from the National Basic Research Program of China(973Program,2011CB504001);the National Natural Science Foundation of China(30873039,81030038,81071661and81000927);the National Key Sci-Tech Special Project of Infectious Diseases(2008ZX10002-022);the Shanghai Rising-Star Follow-up Program Fund(10QH1400500)
BACKGROUND:The prognostic role of diabetes mellitus (DM) coexisting with hepatocellular carcinoma (HCC) remains controversial.To clarify its impact on survival in HCC patients after curative treatments,a meta-analysis...